อ้างอิง ของ ฟาวิพิราเวียร์

  1. ↑ Li G; De Clercq E. (February 2020). "Therapeutic options for the 2019 novel coronavirus (2019-nCoV)". Nature Reviews Drug Discovery. doi:10.1038/d41573-020-00016-0.
  2. ↑ "BRIEF-Corrected-Zhejiang Hisun Pharma gets approval for clinical trial to test flu drug Favipiravir for pneumonia caused by new coronavirus". Reuters Healthcare. 16 February 2020.
  3. ↑ Wang Xiaoyu (15 February 2020). "Drugs with potential against coronavirus in human trials". China Daily.
  4. ↑ Zhang Yangfei (17 February 2020). "First antiviral drug approved to fight coronavirus". China Daily.
  5. 1 2 Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD (June 2009). "T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections". Antiviral Research. 82 (3): 95–102. doi:10.1016/j.antiviral.2009.02.198. PMID 19428599.
  6. ↑ Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL (November 2013). "Favipiravir (T-705), a novel viral RNA polymerase inhibitor". Antiviral Research. 100 (2): 446–54. doi:10.1016/j.antiviral.2013.09.015. PMC 3880838. PMID 24084488.
  7. ↑ Caroline AL, Powell DS, Bethel LM, Oury TD, Reed DS, Hartman AL (April 2014). "Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever". PLoS Neglected Tropical Diseases. 8 (4): e2790. doi:10.1371/journal.pntd.0002790. PMC 3983105. PMID 24722586.
  8. ↑ Mumtaz N, van Kampen JJ, Reusken CB, Boucher CA, Koopmans MP (2016). "Zika Virus: Where Is the Treatment?". Current Treatment Options in Infectious Diseases. 8 (3): 208–211. doi:10.1007/s40506-016-0083-7. PMC 4969322. PMID 27547128.
  9. ↑ Yamada K, Noguchi K, Komeno T, Furuta Y, Nishizono A (April 2016). "Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis". The Journal of Infectious Diseases. 213 (8): 1253–61. doi:10.1093/infdis/jiv586. PMC 4799667. PMID 26655300.
  10. ↑ Murphy J, Sifri CD, Pruitt R, Hornberger M, Bonds D, Blanton J, Ellison J, Cagnina RE, Enfield KB, Shiferaw M, Gigante C, Condori E, Gruszynski K, Wallace RM (January 2019). "Human Rabies - Virginia, 2017". MMWR. Morbidity and Mortality Weekly Report. 67 (5152): 1410–1414. doi:10.15585/mmwr.mm675152a2. PMC 6334827. PMID 30605446.
  11. ↑ Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J (2013). "The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase". PLOS ONE. 8 (7): e68347. Bibcode:2013PLoSO...868347J. doi:10.1371/journal.pone.0068347. PMC 3707847. PMID 23874596.
  12. ↑ Baranovich T, Wong SS, Armstrong J, Marjuki H, Webby RJ, Webster RG, Govorkova EA (April 2013). "T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro". Journal of Virology. 87 (7): 3741–51. doi:10.1128/JVI.02346-12. PMC 3624194. PMID 23325689.
  13. ↑ Guedj J, Piorkowski G, Jacquot F, Madelain V, Nguyen TH, Rodallec A, และคณะ (March 2018). "Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques". PLoS Medicine. 15 (3): e1002535. doi:10.1371/journal.pmed.1002535. PMC 5870946. PMID 29584730.
  14. ↑ Smee DF, Hurst BL, Egawa H, Takahashi K, Kadota T, Furuta Y (October 2009). "Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells". The Journal of Antimicrobial Chemotherapy. 64 (4): 741–6. doi:10.1093/jac/dkp274. PMC 2740635. PMID 19643775.
  15. ↑ Naesens L, Guddat LW, Keough DT, van Kuilenburg AB, Meijer J, Vande Voorde J, Balzarini J (October 2013). "Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir)". Molecular Pharmacology. 84 (4): 615–29. doi:10.1124/mol.113.087247. PMID 23907213.
  16. ↑ Koons C (7 August 2014). "Ebola Drug From Japan May Emerge Among Key Candidates". Bloomberg.com.
  17. ↑ Yoon JJ, Toots M, Lee S, Lee ME, Ludeke B, Luczo JM, และคณะ (August 2018). "Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses". Antimicrobial Agents and Chemotherapy. 62 (8): e00766–18. doi:10.1128/AAC.00766-18. PMC 6105843. PMID 29891600.
  18. ↑ Gatherer D (August 2014). "The 2014 Ebola virus disease outbreak in West Africa". The Journal of General Virology. 95 (Pt 8): 1619–24. doi:10.1099/vir.0.067199-0. PMID 24795448.
  19. ↑ Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S (May 2014). "Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model". Antiviral Research. 105: 17–21. doi:10.1016/j.antiviral.2014.02.014. PMID 24583123.
  20. ↑ Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS (April 2014). "Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model". Antiviral Research. 104: 153–5. doi:10.1016/j.antiviral.2014.01.012. PMID 24462697.
  21. ↑ "First French Ebola patient leaves hospital". Reuters. 4 October 2016.
  22. ↑ "Guinea: Clinical Trial for Potential Ebola Treatment Started in MSF Clinic in Guinea". AllAfrica - All the Time. สืบค้นเมื่อ 28 December 2014.
  23. ↑ Fink S (4 February 2015). "Ebola Drug Aids Some in a Study in West Africa". The New York Times.
  24. ↑ Cohen J (26 February 2015). "Results from encouraging Ebola trial scrutinized". Science. doi:10.1126/science.aaa7912. สืบค้นเมื่อ 21 January 2016.
  25. ↑ "Favipiravir in Patients with Ebola Virus Disease: Early Results of the JIKI trial in Guinea | CROI Conference". www.croiconference.org. สืบค้นเมื่อ 2016-03-17.
  26. ↑ Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, และคณะ (March 2016). "Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea". PLoS Medicine. 13 (3): e1001967. doi:10.1371/journal.pmed.1001967. PMC 4773183. PMID 26930627.
  27. ↑ Gorbalenya, Alexander E.; Baker, Susan C.; Baric, Ralph S.; และคณะ (2020-02-11). "Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group". bioRxiv: 2020.02.07.937862. doi:10.1101/2020.02.07.937862.
  28. ↑ Manli Wang; Ruiyuan Cao; และคณะ (2020-02-04). "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro". Cell Research (Nature).
  29. ↑ "好消息！ 磷酸氯喹等部分药物初步显示良好临床疗效". 科技日报记者 付丽丽 刘垠. 中華人民共和国科学技術部. 2020-02-15. สืบค้นเมื่อ 2020-02-27.
  30. ↑ "瑞德西韦等药物已初步显示良好临床疗效" (in Chinese). 新浪. 2020-02-16.CS1 maint: unrecognized language (link)
  31. ↑ "对战新冠病毒，多种药物和疗法正在临床发挥效力丨科技战疫进行时". 张佳星. 科技日报. 2020-02-13. สืบค้นเมื่อ 2020-02-29.
  32. ↑ "新冠肺炎治疗药物获批上市？别急！注意看这三个字……". 张佳星. 科技日报. 2020-02-17. สืบค้นเมื่อ 2020-02-29.
  33. ↑ "药物研发到了哪一步？ 复产复工如何防感染？ ——疫情防控科技进展焦点透视". 孙奕、董瑞丰、侯雪静. 新华网. 2020-02-21. สืบค้นเมื่อ 2020-02-28.
  34. ↑ "全国首个潜在治新冠肺炎药物"法维拉韦"获批上市" (in Chinese). 新浪. 2020-02-16.CS1 maint: unrecognized language (link)
  35. ↑ "新型インフル薬｢アビガン｣活用も、新型肺炎の治療薬に－加藤厚労相". Bloomberg. 2020-02-02. สืบค้นเมื่อ 2020-02-02.
  36. ↑ "患者にインフル治療薬「アビガン」投与 エボラ薬も". 産経ニュース. 産経新聞社. 2020-02-22. สืบค้นเมื่อ 2020-02-22.
  37. ↑ "コロナにインフル治療薬「アビガン」活用を検討". nikkansports.com. 日刊スポーツ社. 2020-02-22. สืบค้นเมื่อ 2020-02-22.
  38. ↑ "アビガンの投与開始". 47NEWS. 共同通信社. 2020-02-22. สืบค้นเมื่อ 2020-02-22.
  39. ↑ "抗インフルエンザウイルス薬「アビガン錠200mg」の日本国内での製造販売承認取得のお知らせ" (in Japanese). 富山化学工業. 24 March 2014.CS1 maint: unrecognized language (link)
  40. ↑ "エボラ出血熱で世界が注目する日本発のある薬剤". 日経メディカル. 11 August 2014.
  41. ↑ "ファビピラビル製剤の使用に当たっての留意事項について" (PDF) (in Japanese). 厚生労働省. 24 March 2014.CS1 maint: unrecognized language (link)


ยาต้านไวรัสที่ออกฤทธิ์ที่อาร์เอ็นเอของไวรัส (ส่วนใหญ่ J05, รวมถึง S01AD และ D06BB)
ไวรัสตับอักเสบซี
ยับยั้งเอนไซม์ NS3/4A โปรตีเอส (–พรีเวียร์)
ยับยั้งโปรตีน NS5A (–อาสเวียร์)
ยับยั้ง NS5B อาร์เอ็นเอพอลิเมอเรส (–บูเวียร์)
ยาสูตรผสม
พิคอร์นาไวรัส
ไวรัสไข้หวัดใหญ่
หลายกลไก/ทั่วไป
อินเตอร์เฟียรอน
หลายกลไก/ไม่ทราบแน่ชัด

แหล่งที่มา

WikiPedia: ฟาวิพิราเวียร์ http://allafrica.com/stories/201412260651.html http://www.chemspider.com/431002 http://stdaily.com/index/kejixinwen/2020-02/17/con... http://www.stdaily.com/index/kejixinwen/2020-02/13... http://www.stdaily.com/index/kejixinwen/2020-02/15... http://www.xinhuanet.com/politics/2020-02/21/c_112... http://pubchem.ncbi.nlm.nih.gov/summary/summary.cg... //pubmed.ncbi.nlm.nih.gov/19428599 //pubmed.ncbi.nlm.nih.gov/19643775 //pubmed.ncbi.nlm.nih.gov/23325689